Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

Share Price is delayed by 15 minutes
Get Live Data
221.00    -1.00 (-0.45%)
Bid:
221.00
Ask:
232.00
Spread: 11.00 (4.977%)
Market Cap: £116.68m
APTD Live PriceLast checked at - London Stock Exchange

Intraday Aptitude Share Chart

Interim Management Statement

30 Oct 2014 07:00

RNS Number : 6537V
Microgen PLC
30 October 2014
 



microgen

www.microgen.com 30 October 2014

 

INTERIM MANAGEMENT STATEMENT

 

Microgen plc ('Microgen' or 'the Group') provides its Interim Management Statement covering the period from 1 July 2014 to the date of this announcement. Microgen released its interim results for the six months ended 30 June 2014 on 21 July 2014.

 

There have been no significant changes since 1 July 2014 in the trading or financial position of Microgen and its balance sheet remains strong. Both of the Group's businesses, Aptitude Software and Financial Systems, continue to perform satisfactorily in line with the Board's current expectations. In line with the Group's seasonal cash flow cycle and the normal variation in timing of customer receipts the Group had cash at 30 September 2014 of £34.7 million (30 June 2014: £37.9 million) and net funds of £17.7 million (30 June 2014: £20.2 million).

 

Investment has continued in the Aptitude Software business with the release of the latest version of the Aptitude technology platform in October. This software version further extends the Aptitude Big Data processing capabilities enabling users to build data-driven applications deploying Aptitude's in-memory, in-database and in-Hadoop processing. In conjunction with this release, the Aptitude Software business has entered into a partnership with Cloudera, the leading distributor of Apache Hadoop. In October, the Aptitude Software business also released the Compact Edition of the Aptitude Accounting Hub, a pre-configured Aptitude-based divisional accounting hub and sub-ledger which complements the Aptitude Revenue Recognition Engine and the Aptitude Allocation Engine released earlier in the year.

 

In August, Aptitude Software signed a contract with a large North American telecommunications company, which is anticipated to generate revenues in excess of $5 million over its expected term. Discussions are also underway with a number of other telecommunications companies related to the potentially very high volume data processing demands associated with the new IFRS 15 (customer contract revenue recognition) accounting requirements.

 

Financial Systems' wealth management product for trust and fund administration, 5Series, continues to be well received in the market with three new contracts entered into since 1 July 2014. In line with the Board's strategy, the Financial Systems' Application Management business continues to decline slowly as some legacy products/solutions approach end of life. A number of add-on acquisitions in the wealth management sector continue to be progressed, although the Board remains prudent and, as always, there can be no certainty that any acquisitions will be completed.

 

Microgen is continuously identifying and evaluating businesses and strategic investments which the Board believes may benefit from being operated as a business unit under Microgen's stewardship. The Board will maintain its prudent approach and there can be no certainty that any material acquisition will be completed.

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

Philip Wood, Group Finance Director

 

Lucy Delaney, FTI Consulting 020-3727-1131

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSMLBPTMBTTBFI
Date   Source Headline
8th Nov 20132:13 pmRNSHolding(s) in Company
6th Nov 20134:49 pmRNSHolding(s) in Company
6th Nov 20134:46 pmRNSHolding(s) in Company
1st Nov 20131:31 pmRNSPosting of Shareholder Circular
29th Oct 20137:02 amRNSStrategic Review
29th Oct 20137:00 amRNSInterim Management Statement
28th Oct 20134:32 pmRNSHolding(s) in Company
23rd Oct 20131:01 pmRNSHolding(s) in Company
1st Oct 201312:51 pmRNSDirector Declaration
26th Sep 20132:26 pmRNSBlocklisting Interim Review
25th Sep 20134:32 pmRNSHolding(s) in Company
9th Aug 20137:00 amRNSDirectorate Change
22nd Jul 20137:00 amRNSInterim Results
17th Jul 20132:36 pmRNSHolding(s) in Company
15th Jul 20132:19 pmRNSNotice of Interim Results
2nd Jul 20133:16 pmRNSBlocklisting Return
1st Jul 201310:14 amRNSTotal Voting Rights
27th Jun 20131:57 pmRNSHolding(s) in Company
3rd Jun 20139:50 amRNSTotal Voting Rights
13th May 201311:53 amRNSResults of AGM
13th May 20137:00 amRNSInterim Management Statement
1st May 20137:00 amRNSTotal Voting Rights
29th Apr 20135:23 pmRNSHolding(s) in Company
29th Apr 20135:16 pmRNSHolding(s) in Company
9th Apr 201312:11 pmRNSHolding(s) in Company
8th Apr 20135:20 pmRNSHolding(s) in Company
5th Apr 20134:35 pmRNSHolding(s) in Company
2nd Apr 201310:58 amRNSTotal Voting Rights
25th Mar 20134:06 pmRNSBlocklisting Interim Review
21st Mar 20134:53 pmRNSAnnual Information Update
21st Mar 20133:33 pmRNSDirectors Shareholdings
21st Mar 20133:28 pmRNSPDMR Shareholding
8th Mar 20132:37 pmRNSPosting of Annual Report and Notice of AGM
25th Feb 20137:00 amRNSPreliminary Results
19th Feb 20137:00 amRNSNotice of Results
4th Jan 201310:03 amRNSBlocklisting Interim Review
30th Nov 20129:24 amRNSTotal Voting Rights
12th Nov 20127:00 amRNSInterim Management Statement
31st Oct 20123:01 pmRNSTotal Voting Rights
23rd Oct 20122:12 pmRNSHolding(s) in Company
28th Sep 20122:15 pmRNSBlocklisting Interim Review
31st Aug 201210:00 amRNSTotal Voting Rights
31st Jul 20129:51 amRNSTotal Voting Rights
26th Jul 20127:00 amRNSTransaction in Own Shares
25th Jul 20127:00 amRNSTransaction in Own Shares
23rd Jul 20127:00 amRNSInterim Results
13th Jul 201210:32 amRNSNotice of Results
4th Jul 201211:12 amRNSBlocklisting Interim Review
2nd Jul 201211:29 amRNSTotal Voting Rights
30th Apr 20129:44 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.